AstraZeneca (NASDAQ:AZN, OTCPK:AZNCF) ought to be doing victory laps at this point on the back of its ambitious provision of a swiftly developed vaccine it has been rolling out
AstraZeneca: No Longer Overpriced
Summary
- The vaccine supply debate has distracted attention from strong growth at the company.
- I see the vaccine arguments as a sideshow. The company should make some money from the vaccines, but more importantly, its core businesses are in strong growth mode.
- After a pullback in recent months, I now see the shares as fairly valued.
I am a private investor based in the United Kingdom and most interested in equities in the U.K., U.S., Canada and Norway.
Analyst’s Disclosure:I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.